Loading news...
Acuitas Investments LLC increased its position in shares of Accuray Incorporated (NASDAQ: ARAY) by 67.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,392,126 shares of the medical equipment provider's stock after acquiring an additional 966,100 shares during the quarter.
MADISON, Wis., Jan. 21, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2026, ended December 31, 2025, during a conference call hosted by company management at 1:30 p.m.
Check-Cap (NASDAQ: CHEK - Get Free Report) and Accuray (NASDAQ: ARAY - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, risk and earnings. Profitability This table compares Check-Cap and Accuray's net margins,
Accuray Incorporated (NASDAQ: ARAY) announced the first phase of a broad strategic, operational and organizational transformation designed to tighten cost controls, clarify accountability and accelerate execution, with management targeting a meaningful improvement in profitability once the changes are fully implemented.
Accuray outlines a restructuring plan aimed at $25 million in annual profit gains through cost cuts, workforce reduction and operational realignment.
Plan includes organizational realignment, rightsizing of cost structure, outsourcing, and sales enablement in order to enhance competitiveness and support long-term strategy. Workforce optimization actions will affect approximately 15% of the company's employees.
Mesa Laboratories (NASDAQ: MLAB - Get Free Report) and Accuray (NASDAQ: ARAY - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Institutional and Insider Ownership 90.6% of Mesa Laboratories
Accuray reported another weak quarter, with revenue and order declines highlighting ongoing struggles amid recent leadership changes. ARAY's gross margin weakened significantly on sales mix, driving EBITDA into the red, and backlog eroded for the sixth consecutive quarter. A new CEO and transformation plan offer potential, but details are scarce and operational improvements remain uncertain amid entrenched competition.
Accuray Incorporated ( ARAY ) Q1 2026 Earnings Call November 5, 2025 4:30 PM EST Company Participants Stephen Monroe Stephen LaNeve - President, CEO & Director Ali Pervaiz - Senior VP & CFO Conference Call Participants Marie Thibault - BTIG, LLC, Research Division Presentation Operator Good day, and welcome to the Accuray First Quarter Fiscal 2026 Financial Results Conference Call. [Operator Instructions].
MADISON, Wis., Nov. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter ended September 30, 2025.
MADISON, Wis. , Oct. 31, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Stephen La Neve, the company's new Chief Executive Officer.
MADISON, Wis. , Oct. 28, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2026, ended September 30, 2025, during a conference call hosted by company management at 1:30 p.m.
Industry Veteran Steve La Neve Named Chief Executive Officer Suzanne Winter to Retire as President and CEO Company Appoints Steven F. Mayer as Transformation Board Sponsor Chan W.
5D Clinics and Joint Venture Partner Icon Group Make Strides in Delivering on Commitment to Increasing Access to World-class Radiation Treatments for More Communities Across Australia. MADISON, Wis.
MADISON, Wis. , Sept. 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health (UW SMPH) announced today the signing of a memorandum of understanding (MOU) to advance online adaptive radiotherapy (OART) on the Accuray helical radiation treatment delivery platform.
Accuray Incorporated (NASDAQ:ARAY ) Shareholder/Analyst Call September 29, 2025 4:30 PM EDT Company Participants Suzanne Winter - President, CEO & Director Mu Lee - Senior Vice President of Research & Product Development Seth Blacksburg - Senior VP & Chief Medical Officer Conference Call Participants Shalom Kalnicki Jonathan Haas Giuseppe Sasso John Kresl Presentation Suzanne Winter President, CEO & Director Good afternoon, everyone, and welcome to Accuray's Analyst briefing. We're coming to you from the ASTRO conference in San Francisco for 2025.
New Solution Provides an Unprecedented Set of Tools, Empowering Clinical Teams With Choice and Flexibility to Deliver Adaptive Care—Tailoring Radiotherapy to Each Patient's Unique Needs MADISON, Wis. , Sept. 26, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company is advancing its legacy of leadership in adaptive radiotherapy with the introduction of the Accuray Stellar™* Solution.
ARAY sees strong order momentum, APAC growth and CyberKnife demand, but soft product sales and regional headwinds cloud near-term gains.
Event Will Feature Global KOLs Sharing Their Perspectives on the Role of Adaptive Radiotherapy in Radiation Medicine MADISON, Wis. , Sept. 11, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will host a discussion with analysts and investors on Monday, September 29, 2025, in conjunction with the American Society of Radiation Oncology (ASTRO) Annual Meeting in San Francisco, California.
ARAY stock down after Q4 earnings miss estimates, with product sales hit by tariffs and regional demand softness.